This title appears in the Scientific Report :
2019
Please use the identifier:
http://dx.doi.org/10.1097/WCO.0000000000000701 in citations.
Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis
Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis
A variety of high-efficacy disease-modifying therapies (DMTs) are available for the treatment of multiple sclerosis (MS). After evaluation and approval by regulatory agencies, DMTs are likely to be administered to patients whose characteristics differ from those enrolled in clinical trials. This may...
Saved in:
Personal Name(s): | Schweitzer, Finja |
---|---|
Laurent, Sarah / Fink, Gereon Rudolf / Barnett, Michael H. / Reddel, Stephen / Hartung, Hans-Peter / Warnke, Clemens (Corresponding author) | |
Contributing Institute: |
Kognitive Neurowissenschaften; INM-3 |
Published in: | Current opinion in neurology, 32 (2019) 3, S. 305 - 312 |
Imprint: |
[S.l.]
Ovid
2019
|
PubMed ID: |
30985373 |
DOI: |
10.1097/WCO.0000000000000701 |
Document Type: |
Journal Article |
Research Program: |
(Dys-)function and Plasticity |
Publikationsportal JuSER |
A variety of high-efficacy disease-modifying therapies (DMTs) are available for the treatment of multiple sclerosis (MS). After evaluation and approval by regulatory agencies, DMTs are likely to be administered to patients whose characteristics differ from those enrolled in clinical trials. This may contribute to the emergence of unexpected adverse events observed in the real-world setting. Higher age may be a relevant factor that could change the benefit–risk balance of DMTs, as it may associate with lower efficiency and higher frequency of adverse events. |